SPRY250117P30000
- 13.40
- 0.000.00%
ARS Pharmaceuticals Newsroom
Analysts Are Bullish on These Healthcare Stocks: Kura Oncology (KURA), ARS Pharmaceuticals (SPRY)
ARS Pharmaceuticals Price Target Raised to $28.00/Share From $26.00 by Raymond James
Raymond James Maintains Strong Buy on ARS Pharmaceuticals, Raises Price Target to $28
Raymond James Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Raises Target Price to $28
ARS Pharmaceuticals Is Maintained at Outperform by Leerink Partners
ARS Pharmaceuticals Analyst Ratings
Leerink Partners Sticks to Their Buy Rating for ARS Pharmaceuticals (SPRY)
ARS Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Maintains Target Price $30
ARS Pharmaceuticals (SPRY) Initiated With a Buy at Cantor Fitzgerald
ARS Pharmaceuticals Is Maintained at Outperform by Leerink Partners
ARS Pharmaceuticals Analyst Ratings
ARS Pharmaceuticals' Market Expansion and Strategic Positioning Affirm Buy Rating
ARS Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Initiates ARS Pharmaceuticals(SPRY.US) With Buy Rating, Announces Target Price $30
Leerink Partners Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Maintains Target Price $20
Raymond James Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Raises Target Price to $22
ARS Pharmaceuticals Analyst Ratings
ARS Pharmaceuticals Price Target Announced at $18.00/Share by Raymond James
ARS Pharmaceuticals Analyst Ratings